EPAS1 and renal cell carcinoma: Recent studies have led to treating renal cell carcinoma by specifically inhibiting transcriptional activity of HIF2α (not HIF1α) with a small molecule named PT2385 and PT2977 (Wallace et al, 2016; Wehn et al, 2018; Xu et al, 2019).